Vaccinex adds to rally ahead of expected readout from Huntington’s study

Vaccinex (VCNX +18.3%) is up again, although 19% off the intraday high of $6.64, adding to its week-long rally after announcing that it remains on track to complete the pivotal Phase 2 SIGNAL study evaluating lead drug pepinemab in Huntington’s disease patients on schedule. Shares have rallied almost 50% since then.

According to ClinicalTrials.gov, the estimated completion was May so topline data should be available soon.

Pepinemab is a humanized monoclonal antibody that blocks the signaling of a protein called semaphorin 4D (SEMA4D) that regulates the migration and function of immune and inflammatory cells. The company is also investigating its potential in Alzheimer’s disease and progressive multiple sclerosis.

https://seekingalpha.com/news/3591086-vaccinex-adds-to-rally-ahead-of-expected-readout-from-huntingtons-study